Omega-3 Fatty Acids and Skeletal Muscle Health
Open accessThe DOI matches its Crossref record; 179 of the 180 references it cites were found in a registry or an index; 68 of the 207 sources its claims cite were checked for support.
Abstract
Skeletal muscle is a plastic tissue capable of adapting and mal-adapting to physical activity and diet. The response of skeletal muscle to adaptive stimuli, such as exercise, can be modified by the prior nutritional status of the muscle. The influence of nutrition on skeletal muscle has the potential to substantially impact physical function and whole body metabolism. Animal and cell based models show that omega-3 fatty acids, in particular those of marine origin, can influence skeletal muscle metabolism. Furthermore, recent human studies demonstrate that omega-3 fatty acids of marine origin can influence the exercise and nutritional response of skeletal muscle. These studies show that the prior omega-3 status influences not only the metabolic response of muscle to nutrition, but also the functional response to a period of exercise training. Omega-3 fatty acids of marine origin therefore have the potential to alter the trajectory of a number of human diseases including the physical decline associated with aging. We explore the potential molecular mechanisms by which omega-3 fatty acids may act in skeletal muscle, considering the n-3/n-6 ratio, inflammation and lipidomic remodelling as possible mechanisms of action. Finally, we suggest some avenues for further research to clarify how omega-3 fatty acids may be exerting their biological action in skeletal muscle.
Overview
CoChat Summary
TL;DR
This narrative review argues that marine omega-3 PUFAs (EPA/DHA) can influence skeletal muscle metabolism, anabolism, insulin sensitivity, inflammation, and lipidome remodelling, with human evidence strongest for enhanced muscle protein synthesis and some functional benefits. It concludes that human trial results remain mixed, likely due to high n-6/n-3 ratios, individual variation, and unresolved dose/placebo issues.
Key findings
- Human RCTs: 8-week supplementation with 1.86 g EPA + 1.5 g DHA/day augmented the muscle protein synthesis response to a hyperinsulinemic-hyperaminoacidemic clamp in older adults without affecting basal MPS, with a similar trend in young/middle-aged individuals; 6 months of 1.8 g EPA + 1.5 g DHA/day ameliorated age-related declines in lean muscle mass and increased hand grip and 1-RM strength. A 90-day trial of 2 g/day omega-3 plus progressive resistance exercise improved strength and neuromuscular function, but omega-3 alone had no effect.
- In C2C12 myotubes, EPA increased MPS 25% greater than control, while DHA had no effect despite elevated p70S6K1 phosphorylation in both treatments; EPA may reduce protein degradation via NF-κB/MURF-1 signalling, and one study found DHA attenuated degradation more efficiently than EPA.
- Metabolic/insulin findings: 3 weeks of omega-3 supplementation increased fat oxidation by 35% at the expense of glucose utilization after a glucose bolus, but human glucose homeostasis trials are equivocal, with some showing no effect or adverse effects. Proposed protective mechanisms include increased incorporation of fatty acids into complex lipids, reduced inflammatory signalling, and PPARγ/NF-κB effects.
- Inflammation/lipidome: EPA-derived eicosanoids are up to 50%–80% less biologically active than arachidonic acid-derived eicosanoids; the threshold for EPA to reduce prostaglandin E2 was between 1.35 and 2.75 g/day, and muscle total lipid/phospholipid omega-3 enrichment increased approximately two-fold over 4–12 weeks of supplementation.
Methods
- Narrative review synthesizing animal, cell-based, and human studies on omega-3 PUFAs and skeletal muscle health, including two summary tables of studies.
- No systematic search strategy, inclusion criteria, risk-of-bias assessment, or meta-analysis is described (evident from the text).
- Main analysis is a qualitative synthesis of proposed mechanisms: muscle anabolism, metabolic flexibility/insulin resistance, inflammation, and lipidome remodelling.
Limitations
- Stated: human trial results are equivocal; no consensus exists on an effective omega-3 dose, there is no apparent dose-response relationship, and individual variation in tissue uptake/lipidomic response may mask effects.
- Stated: placebo choice is key; high omega-6 corn oil controls may have metabolic effects and may not represent a true placebo, and the authors hypothesize that a high n-6/n-3 ratio limits omega-3 effects.
- Evident: as a narrative review, it does not systematically appraise study quality, and many mechanistic conclusions derive from cell or rodent models and remain to be confirmed in human skeletal muscle.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
47 Valid · 7 Not valid · 82 Not checked · 54 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“there are a number of human, animal and cell studies which support a potential role of omega-3 PUFAs in the treatment of IR/T2D through alterations in muscle metabolism”
§ Omega-3 Fatty Acids and Skeletal Muscle Health > 5. Skeletal Muscle Metabolic Flexibility and Insulin Resistance
What the sources say
- Not checked yetcites [100] Lanza, 2013, Influence of fish oil on skeletal muscle mitochondrial energetics and lipid metabolites during high-fat diet, Am. J. Physiol. Endocrinol. Metab. source
- Partly supportedcites [123] Wu, 2012, Omega-3 fatty acids and incident type 2 diabetes: A systematic review and meta-analysis, Br. J. Nutr. sourceExperimental — accuracy not yet measured
The Introduction reports that animal studies suggest omega-3 PUFAs can improve insulin sensitivity, and the Discussion (ALA and DM risk; page unavailable) describes some human trials with improved markers of insulin resistance. The paper does not establish a treatment role through alterations in muscle metabolism or identify muscle metabolism as the mechanism; it describes hepatic and inflammatory pathways instead and notes mixed human findings. (LLM, conf=0.85)
- Disputedcites [124] Akinkuolie, 2011, Omega-3 polyunsaturated fatty acid and insulin sensitivity: A meta-analysis of randomized controlled trials, Clin. Nutr. sourceExperimental — accuracy not yet measured
The Conclusion (page unavailable) says the meta-analysis is consistent with a lack of omega-3 PUFA effects on insulin sensitivity, rather than evidence for treating insulin resistance. The Discussion (page unavailable) likewise reports no overall association. The cited paper does not establish the proposed muscle-metabolism mechanism or summarize supporting animal and cell studies. (LLM, conf=0.78)
Checked by a reasoning model — may be wrong.
- Partly supportedcites [125] Hartweg, J., Perera, R., Montori, V., Dinneen, S., Neil, H.A.W., and Farmer, A. (2008). Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus. Cochrane Database Syst. Rev., CD003205. sourceExperimental — accuracy not yet measured
The Background (Main results; page not provided) reviews human trials of omega-3 supplementation in type 2 diabetes, supporting that limited part of the claim. It reports no significant effect on glycemic control or fasting insulin, however, and does not establish a treatment effect through muscle metabolism or report supporting animal and cell studies. (LLM, conf=0.85)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Loss of muscle mass with progressing age is an inevitable aspect of the aging process [5].”
§ Omega-3 Fatty Acids and Skeletal Muscle Health > 1. Introduction
What the sources say
- Partly supportedcites [5] Rosenberg, 1997, Sarcopenia: Origins and clinical relevance, J. Nutr. sourceExperimental — accuracy not yet measured
The discussion of age-related decline (p. 990S) describes loss of lean body mass as a striking feature of aging. But the paper asks whether such decline is a necessary part of aging or can be influenced, and suggests strength training might alter it. It therefore does not establish that muscle loss is inevitable. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“While ALA is the preferred substrate for ∆6 desaturase, an abundance of dietary linoleic acid has been shown to suppress conversion of ALA to DHA [33], which may be a confounding factor in these studies.”
§ Omega-3 Fatty Acids and Skeletal Muscle Health > 2. Dietary Fatty Acid Sources and the Influence of the n-3/n-6 Ratio on Metabolic Health
What the sources say
- Supportedcites [33] Smink, 2012, Linoleic and α-linolenic acid as precursor and inhibitor for the synthesis of long-chain polyunsaturated fatty acids in liver and brain of growing pigs, Animal source
The Abstract and Discussion of Smink et al. (2012) report that high LA intake decreased hepatic EPA (~35%) and DHA (~20%) (all P < 0.001), and the Brain/conclusion passage states explicitly that 'high dietary LA intake inhibits the conversion of ALA into n-3 LC-PUFA'. The Discussion also states that D6 desaturase 'has been reported to have a higher affinity for ALA than for LA', covering the first clause of the citing sentence. The effect was demonstrated in liver (and plasma) of growing gilts; the same passages note brain DHA was virtually unaffected by dietary LA and ALA, a limitation of scope rather than a contradiction of the attributed point. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Recent evidence suggests that manipulating the omega-3 polyunsaturated fatty acid (PUFA) content of skeletal muscle may improve muscle function and metabolism [10,11].”
§ Omega-3 Fatty Acids and Skeletal Muscle Health > 1. Introduction
What the sources say
- Partly supportedcites [10] Smith, 2015, Fish oil-derived n-3 PUFA therapy increases muscle mass and function in healthy older adults, Am. J. Clin. Nutr. sourceExperimental — accuracy not yet measured
Smith et al. (2015) support the muscle-function half of the claim: their 6-mo RCT in healthy older adults found increased thigh muscle volume, handgrip strength and 1-RM strength with fish oil-derived n-3 PUFA therapy (Results, 'Effects of n-3 PUFA therapy on body weight, body fat, and muscle mass and function'; Abstract conclusion). The 'metabolism' half is not this trial's own finding — the Discussion mechanism paragraph credits mitochondrial biogenesis/content, reduced intramyocellular triglyceride and increased muscle protein synthesis to cell-culture and animal studies (refs 40, 43-45) and to their earlier 2011 paper (ref 39), and the trial's own metabolic measures (body fat, intermuscular fat, plasma lipids, glucose/OGTT) were all unchanged (Table 2). Also, the intervention was assessed by red blood cell n-3 PUFA content (+135%), not by measured skeletal-muscle PUFA content, so 'manipulating the omega-3 PUFA content of skeletal muscle' is stated at a level this source does not directly demonstrate. (LLM, conf=0.75)
- Not checked yetcites [11] Rodacki, 2012, Fish-oil supplementation enhances the effects of strength training in elderly women, Am. J. Clin. Nutr. source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Yet, when end point measures such as cardiovascular disease are taken together in a meta-analysis the results of omega-3 supplementation are equivocal [40,41,42,43].”
§ Omega-3 Fatty Acids and Skeletal Muscle Health > 2. Dietary Fatty Acid Sources and the Influence of the n-3/n-6 Ratio on Metabolic Health
What the sources say
- Supportedcites [40] Hooper, 2006, Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: Systematic review, BMJ source
The Abstract (p. 1) states that across 48 RCTs 'the trial results were inconsistent' with no strong evidence of reduced risk of combined cardiovascular events (RR 0.95, 0.82 to 1.12), and the 'Combined cardiovascular events' section reports 'no definite effect ... but confidence intervals were wide ... and inconsistency was high (I2 = 65%)'. The Interpretation section makes the equivocity explicit: 'It is not clear whether long chain or short chain omega 3 fats (together or separately) reduce or increase total mortality, cardiovascular events, cancer, or strokes.' The supplementation component is covered too, since subgrouping 'by advice to eat oily fish versus supplements did not generate robust effects of omega 3 fats on cardiovascular events.' (LLM, conf=0.90)
- Not checked yetcites [41] Rizos, 2012, Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: A systematic review and meta-analysis, JAMA source
- Partly supportedcites [42] Akinkuolie, 2012, Fish consumption, omega-3 fatty acids and risk of heart failure: A meta-analysis, Clin. Nutr. sourceExperimental — accuracy not yet measured
Our copy does carry the general point that omega-3 effects on cardiovascular outcomes have been inconsistent: the background section states that although 'marine omega-3 fatty acids may reduce the risk of CHD deaths', 'their association with non-fatal CHD or blood pressure has been inconsistent' and that HF findings 'have not been consistent across studies'. However, this paper is a meta-analysis of observational prospective cohorts of fish intake and biomarker EPA/DHA on incident heart failure (Abstract > Results: 7 studies, 176,441 subjects, pooled RR 0.85 for fish and 0.86 for omega-3), not of omega-3 supplementation trials, and its own pooled conclusion is 'consistent with a lower risk of heart failure' rather than equivocal; the Discussion also concedes the inference is observational and 'cannot exclude chance, residual or unmeasured confounding'. The supplementation element and the 'equivocal overall CVD endpoint' framing are therefore not this source's finding — the inconsistency it describes is credited to other works it cites (e.g. Hooper et al., BMJ 2006; Geleijnse et al., J Hypertens 2002). (LLM, conf=0.70)
- Partly supportedcites [43] Marik, 2009, Omega-3 Dietary Supplements and the Risk of Cardiovascular Events: A Systematic Review, Clin. Cardiol. sourceExperimental — accuracy not yet measured
The Introduction (p. 365-366) does state that 'the results of prospective interventional studies and meta-analyses have produced mixed results,' which partly matches the claim's 'equivocal' framing, but that remark is about earlier meta-analyses (their refs 8-11), not about Marik and Varon's own pooled result. Their own meta-analysis of 11 trials (39 044 patients; Discussion) concludes that supplementation for a year or longer 'significantly reduces the risk of cardiovascular deaths, sudden cardiac death, all-cause mortality, and nonfatal cardiovascular events' (e.g. CV-death OR 0.87 [0.76, 0.99], p = 0.04; overall nonfatal/CV-event ORs 0.92 [0.85, 0.99] and 0.87 [0.79, 0.95]), i.e. a definite benefit rather than an equivocal one. So the part of the claim that this source's own end-point meta-analysis is equivocal is not supported. (LLM, conf=0.70)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
96 more claims · 33 with their cited sources checked
Create a free account to see all 190 claims and to verify the 139 references still open.
- It may state two separate claims as one. 78
- Probably not a substantial claim. 23
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Omega-3 PUFAs may influence skeletal muscle health and function [89]”
From Is There Enough Evidence for Osteosarcopenic Obesity as a Distinct Entity? A Critical Literature Review (2019) · cites this paper as [89]
In the citing paper
“The omega-3 PUFAs (DHA and EPA) are known for their anti-inflammatory properties [32], and marine-derived omega-3 PUFAs can influence the exercise and nutritional response of skeletal muscle [33].”
From Novel Insights on Intake of Fish and Prevention of Sarcopenia: All Reasons for an Adequate Consumption (2020) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Omega-3 Fatty Acids and Skeletal Muscle Health > 4. Skeletal Muscle Anabolism
“| Smith et al. (2011) [63] | Human | 8 weeks, 1.86 g EPA, 1.5 g DHA daily | Augmented MPS and enahnced mTOR and p70S6K1 signalling in response to a hyperaminoacidemic-hyperinsulinemic clamp in young volunteer. |”
§ Omega-3 Fatty Acids and Skeletal Muscle Health > References
“63. Smith G.I. Atherton P. Reeds D.N. Mohammed B.S. Rankin D. Rennie M.J. Mittendorfer B. Dietary omega-3 fatty acid supplementation increases the rate of muscle protein synthesis in older adults: A randomized controlled trial”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Omega-3 Fatty Acids and Skeletal Muscle Health > 3. EPA vs. DHA
“docosapentaenoic acid (DHA, 22:6)”
§ Omega-3 Fatty Acids and Skeletal Muscle Health > 2. Dietary Fatty Acid Sources and the Influence of the n-3/n-6 Ratio on Metabolic Health
“docosahexaenoic acid (DHA 22:6n-3)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Omega-3 Fatty Acids and Skeletal Muscle Health > 2. Dietary Fatty Acid Sources and the Influence of the n-3/n-6 Ratio on Metabolic Health
“this n-3/n-6 ratio began to diverge and now in the typical western diet is thought to be as much as 20:1”
§ Omega-3 Fatty Acids and Skeletal Muscle Health > 3. EPA vs. DHA
“The typical western diet, however, is deficient in omega-3 PUFAs and abundant in omega-6 fatty acids [54].”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Omega-3 Fatty Acids and Skeletal Muscle Health > 2. Dietary Fatty Acid Sources and the Influence of the n-3/n-6 Ratio on Metabolic Health
“alpha-linoleic acid (ALA 18:3n-3)”
§ Omega-3 Fatty Acids and Skeletal Muscle Health > 2. Dietary Fatty Acid Sources and the Influence of the n-3/n-6 Ratio on Metabolic Health
“supplementing with stearidonic acid (18:3n-3) may improve the efficiency of conversion to DHA”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Omega-3 Fatty Acids and Skeletal Muscle Health > 2. Dietary Fatty Acid Sources and the Influence of the n-3/n-6 Ratio on Metabolic Health
“LA is converted to arachidonic acid (AA 22:4n-6).”
§ Omega-3 Fatty Acids and Skeletal Muscle Health > 6. Inflammation
“arachidonic acid (AA, 20:4)”
1 more finding
Create a free account to see every finding of this check.
Citations
Cites
Adipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin Resistance
Hotamisligil, G. S., Shargill, N. S., & Spiegelman, B. M. (1993) · Science · doi:10.1126/science.7678183 · Cited by 7,518
Lipid rafts as a membrane-organizing principle
Lingwood, D., & Simons, K. (2010) · Science · doi:10.1126/science.1174621 · Cited by 4,417 · cited 1×
“and are formed in order to allow the compartmentalisation of the membrane for the coordination of function by providing scaffolding to stabilise protein-protein and lipid-lipid interactions involved in signal transduction and trafficking [172].”
BackgroundEvidence for the Formation of Symmetric and Asymmetric DLPC-DAPC Lipid Bilayer Domains
Ritter, M., Schmidt, S., Jakab, M., Paulmichl, M., & Henderson, R. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350122 · Cited by 3,923
Mutation of the mouse klotho gene leads to a syndrome resembling ageing
Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837
Identification of ubiquitin ligases required for skeletal muscle atrophy.
Bodine, S. C., Latres, E., Baumhueter, S., Lai, V. K.-M., Nunez, L., Clarke, B. A., Poueymirou, W. T., Panaro, F. J., Na, E., Dharmarajan, K., et al. (2001) · Science · doi:10.1126/science.1065874 · Cited by 3,521 · cited 2×
“Animal models that lack MURF-1 expression are protected from atrophy [71,72].”
BackgroundOh, D. Y., Talukdar, S., Bae, E. J., Imamura, T., Morinaga, H., Fan, W., Li, P., Lu, W. J., Watkins, S. M., & Olefsky, J. M. (2010) · Cell · doi:10.1016/j.cell.2010.07.041 · Cited by 2,428
Sarcopenia: origins and clinical relevance
Rosenberg, I. H. (1997) · The Journal of Nutrition · doi:10.1093/jn/127.5.990s · Cited by 2,399
Dysfunction of Mitochondria in Human Skeletal Muscle in Type 2 Diabetes
Kelley, D. E., He, J., Menshikova, E. V., & Ritov, V. B. (2002) · Diabetes · doi:10.2337/diabetes.51.10.2944 · Cited by 2,321
Protection from obesity-induced insulin resistance in mice lacking TNF-α function
Uysal, K. T., Wiesbrock, S. M., Marino, M. W., & Hotamisligil, G. S. (1997) · Nature · doi:10.1038/39335 · Cited by 2,234 · cited 1×
“genetically down regulated demonstrate that preventing obesity induced inflammation can prevent the development of insulin resistance [159,160].”
BackgroundEsposito, K., Marfella, R., Ciotola, M., Di Palo, C., Giugliano, F., Giugliano, G., D'Armiento, M., D'Andrea, F., & Giugliano, D. (2004) · JAMA · doi:10.1001/jama.292.12.1440 · Cited by 2,126
Cited by
Omega-3 Polyunsaturated Fatty Acids: Benefits and Endpoints in Sport
Gammone, M. A., Riccioni, G., Parrinello, G., & D’Orazio, N. (2018) · Nutrients · doi:10.3390/nu11010046 · Cited by 326
“In addiction, a reduction in circulating tumor necrosis factor α (TNF-α) concentrations, as well as in the expression of inflammatory cytokines and cell surface adhesion molecules has been observed [33].”
BackgroundChanges in Plasma Free Fatty Acids Associated with Type-2 Diabetes
I. S. Sobczak, A., A. Blindauer, C., & J. Stewart, A. (2019) · Nutrients · doi:10.3390/nu11092022 · Cited by 304
“A large body of work has been dedicated to long-chain n-3 PUFAs [69,71,128,134,265,266], whilst less information is available for MUFAs [145,267] and n-6 PUFAs [208].”
Backgroundω-3 and ω-6 Polyunsaturated Fatty Acids, Obesity and Cancer
D’Angelo, S., Motti, M. L., & Meccariello, R. (2020) · Nutrients · doi:10.3390/nu12092751 · Cited by 250
“In addition to ALA, ω-3 PUFAs can be defined as a heterogeneous mix of FAs, among which eicosapentaenoic acid (EPA, 20:5n-3) and docosapentaenoic acid (DHA, 22:6n-3) are presently thought to be the most bioactive of theω-3 species; however, docosapentaenoic acid (DPA, 22:5), an intermediate of EPA and DHA, may also ha…”
BackgroundInfluentialDietary Supplements for Health, Adaptation, and Recovery in Athletes
Rawson, E. S., Miles, M. P., & Larson-Meyer, D. E. (2018) · International Journal of Sport Nutrition and Exercise Metabolism · doi:10.1123/ijsnem.2017-0340 · Cited by 201
“Omega 3-fatty acids: Dose most commonly studied is about 2 g/day (Jeromson et al., 2015; Mickleborough, 2013).”
BackgroundAthletes’ nutritional demands: a narrative review of nutritional requirements
Amawi, A., AlKasasbeh, W., Jaradat, M., Almasri, A., Alobaidi, S., Hammad, A. A., Bishtawi, T., Fataftah, B., Turk, N., Saoud, H. A., et al. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1331854 · Cited by 154
“It is recommended to take omega-3 after or with a high-fat meal for optimal absorption (79).”
Background
Metadata
- Authors
- Jeromson, S., Gallagher, I., Galloway, S., & Hamilton, D.
- Affiliations
- University of Stirling (GB)
- Corresponding author
- Hamilton, D.
- Venue
- Marine Drugs
- Publisher
- MDPI AG
- Published
- 2015-11-19
- Volume
- 13
- Issue
- 11
- Pages
- 6977-7004
- ISSN
- 1660-3397 (ISSN-L)
- PMC
- PMC4663562
- OpenAlex
- W2174795486
- Semantic Scholar
- 55dad5cb9aa9bf449acfeaa34ba99c6212c5c4fb
- Cited by
- 203
- References
- 180
- Citations by year
- 2026: 20 · 2025: 20 · 2024: 21 · 2023: 15 · 2022: 17 · 2021: 20 · 2020: 30 · 2019: 22 · 2018: 21 · 2017: 11 · 2016: 6
- FWCI
- 1.63
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Marine Drugs (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Own your potential (DEAKIN) (submittedVersion)
- Stirling Online Research Repository (University of Stirling) (submittedVersion, cc-by)
- Figshare (submittedVersion, cc-by)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Nursing › Nutrition and Dietetics › Muscle metabolism and nutrition
- Health Sciences › Medicine › Physiology (medical) › Exercise and Physiological Responses
- Keywords
- omega-3 fatty acids, skeletal muscle, muscle metabolism, exercise training response, n-6/n-3 ratio, inflammation, aging, physical function, muscle plasticity
- MeSH terms
- Aging, Animals, Humans, Inflammation, Fatty Acids, Omega-3, Muscle, Skeletal, Aquatic Organisms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Omega-3 Fatty Acids and Skeletal Muscle Health. https://app.cochat.ai/papers/10.3390/md13116977
- The paper
- Jeromson, S., Gallagher, I., Galloway, S., & Hamilton, D. (2015). Omega-3 Fatty Acids and Skeletal Muscle Health. Marine Drugs. https://doi.org/10.3390/md13116977
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
